Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Risks of strict glycaemic control in diabetic nephropathy

A 6-year follow-up study of the ADVANCE trial participants reports that intensive glycaemic control is renoprotective—but does not reduce mortality—in patients with type 2 diabetes mellitus. By contrast, a post hoc analysis of the ACCORD trial suggests that intensive glycaemic control might increase mortality in patients with diabetic nephropathy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).

  2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).

  3. Zoungas, S. et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392–1406 (2014).

    Article  Google Scholar 

  4. Papademetriou, V. et al. Chronic kidney disease and intensive glycaemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. http://dx.doi.org/10.1038/ki.2014.296.

  5. Perkovic, V. et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517–523 (2013).

    Article  CAS  Google Scholar 

  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 3, 1–150 (2013).

  7. Chan, S. et al. Complete inhibition of the renin-angiotensin-aldosterone system: where do we stand? Curr. Opin. Nephrol. Hypertens. 23, 449–454 (2014).

    Article  Google Scholar 

  8. Humalda, J. K. et al. Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 23, 533–540 (2014).

    Article  CAS  Google Scholar 

  9. Espeland, M. A. et al. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care 37, 2548–2556 (2014).

    Article  Google Scholar 

  10. Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gerjan Navis.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Borst, M., Navis, G. Risks of strict glycaemic control in diabetic nephropathy. Nat Rev Nephrol 11, 5–6 (2015). https://doi.org/10.1038/nrneph.2014.209

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.209

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing